SUMMARY The effect of xamoterol, a beta1 adrenoceptor partial agonist, on resting haemodynamic measurements and exercise tolerance was studied in 10 patients with dyspnoea of effort. All We studied the effect of xamoterol on resting haemodynamic variables and exercise tolerance in patients with exertional dyspnoea caused by angio-
SUMMARY The effect of xamoterol, a beta1 adrenoceptor partial agonist, on resting haemodynamic measurements and exercise tolerance was studied in 10 patients with dyspnoea of effort. All patients had poor left ventricular function due to myocardial infarction with ejection fractions ranging from 15% to 35% (mean 28%). The cardiac index and stroke work index both rose significantly. The mean pulmonary artery pressure fell from 20(2) mm Hg to 16(2) mm Hg and pulmonary artery wedge pressure from 14(2) mm Hg to 10(2) mm Hg within the first four hours. Exercise tolerance, measured on the treadmill, increased significantly in seven patients but was unchanged in the three who had the lowest left ventricular ejection fractions. Exercise heart rate response was attenuated by the drug in all patients.
It is concluded that xamoterol may be beneficial in patients with poor left ventricular function but can be harmful in extremely poor left ventricular function where high sympathetic drive may be important.
Xamoterol {( +/ -)-1-(4-hydroxyphenoxy)-3-[2-
(4-morpholine carbonamido)ethylamino]-propan-2-ol fumarate)} has been shown in animal experiments to be a beta1 adrenoceptor partial agonist with little effect on arterial impedance.' Its partial agonist or intrinsic sympathomimetic activity amounts (at its maximum) to 45% of the maximum activity of the full agonist isoprenaline. Previous studies in volunteers showed that at rest it has positive inotropic properties as indicated by shortening of the systolic time intervals and rise in systolic blood pressure. supine and without premedication, using a flow directed thermodilution catheter. Baseline measurements of pulmonary artery systolic and diastolic pressure, mean pulmonary artery pressure, mean pulmonary capillary wedge pressure, and heart rate were recorded. Cardiac output was measured in triplicate using a Gould Cardiac Index Computer Model SP1435 (Gould Inc., Oxnard, USA). Systemic arterial pressure was measured by a standard sphygmomanometer. Electrocardiographic monitoring was maintained throughout the study. After the baseline haemodynamic variables were measured xamoterol 200 mg was given orally and the measurements repeated 1, 2, 4, 6, and 12 hours later.
Late-During the eighth week of the trial right heart catheterisation was repeated at rest with the patient supine, without premedication, and before the morning dose of xamoterol. After the baseline haemodynamic variables were measured xamoterol 200 mg was given orally and the measurements repeated one and two hours later. OUTPATIENT 
Results

RESTING HAEMODYNAMIC VARIABLES
On administration of the drug there was an increase in cardiac index and a fall in pulmonary artery pressure. Maximum change in the haemodynamic variables occurred within four hours of giving xamoterol (Table  2 (Fig. 4 c) . The maximum change in mean pulmonary artery pressure from 20(2) mm Hg to 16(2) mm Hg occurred at four hours (p<0001) and in pulmonary capillary wedge pressure from 14(2) mm Hg to 10(2) mm Hg at one hour (p<001) ( Table 2 , Fig. 2) .
Heart rate was not significantly altered in the group as a whole, the control heart rate being 69(6) beats/ min and 76(5) at four hours (Table 2 ). Nevertheless, in the seven patients who subsequently showed an improvement in exercise tolerance the heart rate rose from 69 (6) to 80(5) beats/min at four hours (p<005) (Fig. 3 a) .
EXERCISE TESTING
All patients had appreciably impaired exercise tolerance before treatment (Fig. 5, Table 3 ). After two weeks' treatment with xamoterol there was a significant improvement in exercise tolerance in seven patients (p<0O05) (Fig. 3) . One patient failed to show The change in exercise tolerance with the drug was significantly greater than that with placebo (p<OO5) ( Table 3 ). The increase in heart rate with xamoterol after maximal exercise was significantly lower than that with placebo (p<O005) (Fig. 3 b) . At low levels of sympathetic activity it acts as a beta, adrenoceptor agonist as shown by the increase in stroke volume, left ventricular stroke work index, and heart rate and the fall in pulmonary capillary wedge pressure that occurred in most patients. The fall in systemic vascular resistance is probably the result of increased cardiac output promoting a reduction in endogenous sympathetic activity rather than a direct vasodilator action. Certainly, work in animals has shown that the drug is not a vasodilator. It is likely that in the two patients in whom the drug did not have a positive inotropic or positive chronotropic effect sympathetic tone was higher and the drug acted as a beta adrenoceptor antagonist. These two patients had the lowest ejection fractions of the group.
The patients in whom the drug caused a positive chronotropic effect at rest experienced an improvement in exercise tolerance, whereas those in whom the drug had a negative chronotropic effect and who presumably had higher levels of sympathetic activity at rest did not benefit in terms of exercise tolerance.
The results from this small study suggest that whereas the drug can be given safely and with benefit to patients with poor left ventricular function (mean ejection fraction 28%) it may be harmful to patients with extremely poor ventricular function who depend on high levels of sympathetic nervous system activity.
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